このページの翻訳は実験的なもので、現在開発中です。お待ちしております
CureVac 将来の成長
Future 基準チェック /06
CureVac利益と収益がそれぞれ年間35.1%と7.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-16.8% 37.4%なると予測されています。
主要情報
37.1%
収益成長率
39.0%
EPS成長率
Biotechs 収益成長 | 29.0% |
収益成長率 | 7.9% |
将来の株主資本利益率 | -15.1% |
アナリストカバレッジ | Good |
最終更新日 | 13 Sep 2024 |
今後の成長に関する最新情報
Recent updates
CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk
Sep 16CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price
Aug 03We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
Jul 05CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas
Jul 04Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking
Jun 01We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20CureVac: No Momentum In Sight
Mar 08What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
Aug 26CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 14Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 01Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
Apr 29An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08CureVac BV reports Q2 results
Aug 18CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
Jul 05Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28CureVac: Wait For Concrete News Before Investing
Sep 01CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy
Jun 16An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13CureVac tumbles on potential delay for European decision on its COVID-19 shot
Jun 08CureVac: The Moment Of Truth Arrives
Jun 01CureVac BV reports Q1 results
May 26CureVac Could Soon Join The Fight Against COVID-19
May 10CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability
May 02業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | 107 | -102 | -21 | N/A | 6 |
12/31/2025 | 72 | -120 | 44 | N/A | 8 |
12/31/2024 | 161 | -126 | 21 | N/A | 7 |
6/30/2024 | 66 | -278 | -330 | -290 | N/A |
3/31/2024 | 59 | -273 | -312 | -265 | N/A |
12/31/2023 | 54 | -260 | -323 | -268 | N/A |
9/30/2023 | 43 | -302 | -335 | -273 | N/A |
6/30/2023 | 38 | -301 | -325 | -249 | N/A |
3/31/2023 | 50 | -291 | -338 | -249 | N/A |
12/31/2022 | 67 | -249 | -379 | -286 | N/A |
9/30/2022 | 97 | -122 | -527 | -420 | N/A |
6/30/2022 | 115 | -219 | -758 | -659 | N/A |
3/31/2022 | 117 | -313 | -782 | -673 | N/A |
12/31/2021 | 103 | -412 | -861 | -733 | N/A |
9/30/2021 | 68 | -468 | -228 | -109 | N/A |
6/30/2021 | 44 | -361 | N/A | N/A | N/A |
3/31/2021 | 56 | -219 | 250 | 329 | N/A |
12/31/2020 | 49 | -129 | 475 | 522 | N/A |
9/30/2020 | 50 | -107 | 36 | 62 | N/A |
3/31/2020 | 17 | -102 | -82 | -67 | N/A |
12/31/2019 | 17 | -100 | -99 | -87 | N/A |
12/31/2018 | 13 | -71 | -89 | -74 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: CVAC今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: CVAC今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: CVAC今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: CVACの収益 ( 7.8% ) US市場 ( 8.8% ) よりも低い成長が予測されています。
高い収益成長: CVACの収益 ( 7.8% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: CVAC 3 年以内に赤字になると予測されています。